secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0001193125-24-086609
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx pulls RELYVRIO from market after Phase 3 miss, cuts 70% of staff
-----------------------------------------------------------------------

- Voluntarily discontinues RELYVRIO/ALBRIOZA in U.S. and Canada; no new patients after today.
- Workforce reduced ~70%; expects $19M in severance charges; cash runway extended into 2026.
- Current patients may transition to free drug program; PHOENIX Open Label Extension ongoing.
- Interim data from Phase 2 HELIOS (AMX0035 in Wolfram) due April 2024; webcast Apr 10.
- AMX0114 for ALS expects to start clinical trial in 2H 2024; ORION PSP interim analysis mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524086609/0001193125-24-086609-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312524086609/d780895d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-086609

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer